Sophia Bakhtadze
Sophia Bakhtadze has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Agustí Rodríguez-Palmero
Paediatric Neurology Unit, Department of Pediatrics, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain
1 shared publication - Alexander Schulz
Leibniz Institute on Aging, Fritz Lipmann Institute, Jena, Germany
1 shared publication - Alexandra Montavont
Department of Functional Neurology and Epileptology Hospices Civils de Lyon (Lyon University Hospital), Hospital for Neurology and Neurosurgery Pierre Wertheimer Lyon France
1 shared publication - Angela Clara-Hwang1 shared publication
- Anita Rauch
Institute of Medical Genetics, University of Zurich, Schlieren, Zurich, Switzerland
1 shared publication - Anne-Lise Poulat
Service de Neurologie Pédiatrique, Groupement Hospitalier Est, Hospices Civils de Lyon, 59, boulevard pinel, Bron 69677, France
1 shared publication
Latest Publications
- Open Access
- 1 August 2024
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 10 (4) , e200168
Expanding the Mutational Landscape and Clinical Phenotype of CHD2-Related Encephalopathy
To present a case series of novel CHD2 variants in patients presenting with genetic epileptic and developmental encephalopathy. CHD2 gene encodes an ATP-dependent enzyme, chromodomain helicase DNA-binding protein 2, involved in chromatin remodeling. Pathogenic variants in CHD2 are linked to early-onset conditions such as developmental and epileptic encephalopathy, drug-resistant epilepsies, and neurodevelopmental disorders. Approximately 225 diagnosed patients from 28 countries exhibit various allelic variants in CHD2, including small intragenic deletions/insertions and missense, nonsense, and splice site variants. We present the molecular and clinical characteristics of 17 unreported individuals from 17 families with novel pathogenic or likely pathogenic variants in CHD2. All individuals presented with severe global developmental delay, childhood-onset myoclonic epilepsy, and additional neuropsychiatric features, such as behavioral including autism, ADHD, and hyperactivity. Additional findings include abnormal reflexes, hypotonia and hypertonia, motor impairment, gastrointestinal problems, and kyphoscoliosis. Neuroimaging features included hippocampal signal alterations (4/10), with additional volume loss in 2 cases, inferior vermis hypoplasia (7/10), mild cerebellar atrophy (4/10), and cerebral atrophy (1/10). Our study broadens the geographic scope of CHD2-related phenotypes, providing valuable insights into the prevalence and clinical characteristics of this genetic disorder in previously underrepresented populations.
- 1 August 2024
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 10 (4) , e200168
Open AccessExpanding the Mutational Landscape and Clinical Phenotype of CHD2-Related Encephalopathy
To present a case series of novel CHD2 variants in patients presenting with genetic epileptic and developmental encephalopathy. CHD2 gene encodes an ATP-dependent enzyme, chromodomain helicase DNA-binding protein 2, involved in chromatin remodeling. Pathogenic variants in CHD2 are linked to early-onset conditions such as developmental and epileptic encephalopathy, drug-resistant epilepsies, and neurodevelopmental disorders. Approximately 225 diagnosed patients from 28 countries exhibit various allelic variants in CHD2, including small intragenic deletions/insertions and missense, nonsense, and splice site variants. We present the molecular and clinical characteristics of 17 unreported individuals from 17 families with novel pathogenic or likely pathogenic variants in CHD2. All individuals presented with severe global developmental delay, childhood-onset myoclonic epilepsy, and additional neuropsychiatric features, such as behavioral including autism, ADHD, and hyperactivity. Additional findings include abnormal reflexes, hypotonia and hypertonia, motor impairment, gastrointestinal problems, and kyphoscoliosis. Neuroimaging features included hippocampal signal alterations (4/10), with additional volume loss in 2 cases, inferior vermis hypoplasia (7/10), mild cerebellar atrophy (4/10), and cerebral atrophy (1/10). Our study broadens the geographic scope of CHD2-related phenotypes, providing valuable insights into the prevalence and clinical characteristics of this genetic disorder in previously underrepresented populations.